Form 4: Agios Pharmaceuticals Director Kaye Foster-Cheek Reports Stock Transaction
SEC Form 4 Filing
Director Kaye Foster-Cheek reported a transaction involving Agios Pharmaceuticals stock on March 7, 2024.
Summary
- On March 7, 2024, Kaye Foster-Cheek, a director of Agios Pharmaceuticals, reported a transaction involving the company's common stock.
- She disposed of 1,285 shares at a price of $31.62 per share.
- Following the transaction, Foster-Cheek directly owns 5,524 shares of common stock and indirectly owns 2,200 shares through the Foster Family Revocable Trust.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing related to a stock transaction by a company director. It doesn't inherently indicate positive or negative sentiment.
Industry Context
Form 4 filings are standard disclosures required by the SEC when corporate insiders (officers, directors, and 10% owners) buy or sell their company's stock. These filings provide transparency to the market regarding insider transactions.
Stakeholder Impact
- The transaction may have a minor impact on shareholders as it provides insight into the actions of a company director.
Key Dates
| Date | Description |
|---|---|
| 03/07/2024 | Date of stock transaction |
| 03/11/2024 | Date of signature on the report |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.